{"id":"conversion-from-tacrolimus-to-sirolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Delayed wound healing"},{"rate":null,"effect":"Mouth ulcers"},{"rate":null,"effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus and sirolimus are both immunosuppressive drugs commonly used in transplant recipients, but they work through different mechanisms. Tacrolimus inhibits calcineurin and T-cell activation, while sirolimus inhibits mTOR and blocks T-cell and B-cell proliferation. The conversion strategy aims to reduce tacrolimus-related nephrotoxicity and other adverse effects while maintaining immunosuppression through an alternative mechanism.","oneSentence":"Conversion from tacrolimus to sirolimus involves switching from a calcineurin inhibitor to an mTOR inhibitor, both immunosuppressive agents used to prevent organ rejection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:17.951Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients (conversion from tacrolimus)"},{"name":"Reduction of tacrolimus-related nephrotoxicity in transplant patients"}]},"trialDetails":[{"nctId":"NCT02711826","phase":"PHASE1, PHASE2","title":"Treg Therapy in Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-09-20","conditions":"Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant","enrollment":32},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT03413722","phase":"","title":"Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-02-01","conditions":"End Stage Renal Disease","enrollment":30},{"nctId":"NCT00896012","phase":"PHASE4","title":"Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-01","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT01936519","phase":"NA","title":"Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2013-12-16","conditions":"Immunosuppression, Renal Failure","enrollment":24},{"nctId":"NCT03415750","phase":"PHASE4","title":"Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants","status":"COMPLETED","sponsor":"Edoardo Melilli","startDate":"2016-11","conditions":"Hypertrophy, Left Ventricular","enrollment":20},{"nctId":"NCT00713284","phase":"PHASE4","title":"Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic","status":"COMPLETED","sponsor":"California Pacific Medical Center Research Institute","startDate":"2007-05","conditions":"Renal Transplantation","enrollment":29},{"nctId":"NCT00866879","phase":"PHASE4","title":"Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":"Renal Transplant Rejection","enrollment":275},{"nctId":"NCT01544491","phase":"PHASE3","title":"Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08-17","conditions":"Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant","enrollment":106},{"nctId":"NCT01114529","phase":"PHASE3","title":"Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08-09","conditions":"Kidney Transplantation","enrollment":828},{"nctId":"NCT01269684","phase":"PHASE4","title":"Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08","conditions":"Kidney Transplantation","enrollment":""},{"nctId":"NCT00834496","phase":"","title":"Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2009-01","conditions":"Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic Fibrosis on Biopsy","enrollment":""},{"nctId":"NCT01964014","phase":"PHASE4","title":"Once-a-day Immunosuppression(CISECON_a_day)","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2013-10","conditions":"Chronic Renal Disease","enrollment":160},{"nctId":"NCT01005706","phase":"NA","title":"Sirolimus Conversions in African-American Renal Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-08","conditions":"Absence; Kidney","enrollment":40},{"nctId":"NCT01561404","phase":"PHASE4","title":"Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise","status":"TERMINATED","sponsor":"Josep M Cruzado","startDate":"2011-09","conditions":"Disorder Related to Renal Transplantation, Exercise, Aerobic, Muscle Strength","enrollment":3},{"nctId":"NCT01678937","phase":"","title":"Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-09","conditions":"Liver Transplant Rejection, Immunosuppression","enrollment":31},{"nctId":"NCT00311311","phase":"PHASE3","title":"Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-04","conditions":"Atherosclerosis, Kidney Failure","enrollment":72},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1},{"nctId":"NCT00777400","phase":"PHASE1, PHASE2","title":"Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2008-12","conditions":"Autoimmune Diseases","enrollment":""},{"nctId":"NCT01802268","phase":"PHASE4","title":"Planned Conversion From TAC to SRL-based Regimen in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Helio Tedesco Silva Junior","startDate":"2008-02","conditions":"Kidney Transplant","enrollment":320},{"nctId":"NCT00452361","phase":"PHASE4","title":"Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Kidney Transplantation","enrollment":31},{"nctId":"NCT01399242","phase":"PHASE4","title":"Efficacy of Certican® in Combination With Myfortic® in Renal","status":"UNKNOWN","sponsor":"Hospital Universitário São José","startDate":"2011-08","conditions":"Disorder Related to Renal Transplantation","enrollment":40},{"nctId":"NCT00369382","phase":"PHASE4","title":"Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-09","conditions":"Graft Rejection, Kidney Failure","enrollment":121},{"nctId":"NCT00273871","phase":"PHASE3","title":"Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-01","conditions":"Graft Rejection, Kidney Failure, Kidney Transplantation","enrollment":190},{"nctId":"NCT00038948","phase":"PHASE3","title":"Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-01","conditions":"Renal Transplantation","enrollment":830},{"nctId":"NCT00086346","phase":"PHASE3","title":"Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-12","conditions":"Liver Transplantation","enrollment":607},{"nctId":"NCT00999258","phase":"PHASE4","title":"Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients","status":"UNKNOWN","sponsor":"Temple University","startDate":"2009-09","conditions":"Glomerular Filtration Rate, Chronic Allograft Nephropathy","enrollment":50},{"nctId":"NCT00166842","phase":"PHASE4","title":"Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2002-09","conditions":"Transplantation, Kidney Transplantation, Immunosuppression","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":166,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Conversion from Tacrolimus to Sirolimus","genericName":"Conversion from Tacrolimus to Sirolimus","companyName":"Helio Tedesco Silva Junior","companyId":"helio-tedesco-silva-junior","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conversion from Tacrolimus to Sirolimus is a treatment approach studied in clinical trials for conditions such as kidney transplant and chronic allograft nephropathy. Sirolimus, a small molecule inhibitor of the FK506-binding protein 1A, works by inhibiting the peptidyl-prolyl cis-trans isomerase FKBP1A.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}